From the Department of Ophthalmology, Shanghai Ninth People's Hospital affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, China.
From the Department of Ophthalmology, Shanghai Ninth People's Hospital affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, China.
J Cataract Refract Surg. 2017 Feb;43(2):201-206. doi: 10.1016/j.jcrs.2016.11.048.
To evaluate the macular and subfoveal choroidal thickness variation and macular sensitivity changes in diabetic patients after intracameral cefuroxime in cataract surgery.
Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai, China.
Prospective case series.
Diabetic patients with visually significant cataract were divided into a treatment group, which received an intracameral injection of 1 mg/0.1 mL cefuroxime, and a control group, which received an equal volume of 0.9% saline solution. The macular thickness and subfoveal choroidal thickness were measured by optical coherence tomography. The macular sensitivity was assessed by microperimetry using the MP-1.
The study comprised 46 eyes of 38 patients. The macular thickness increased significantly both in the treatment group (P < .01) and the control group (P < .05) postoperatively. The mean variation was 8.27 ± μm 3.22 (SD) in the treatment eyes and 11.38 ± 7.75 μm in the control eyes. The mean preoperative subfoveal choroidal thickness was 262.86 ± 37.02 μm and 279.70 ± 54.68 μm, respectively (P = .497). No statistical difference was found in the macular thickness variation (P = .338) or subfoveal choroidal thickness variation (P = .491) between the 2 groups. For macular sensitivity, there was no significant difference in the variation between the treatment group and the control group (6.05 ± 2.37 dB versus 5.52 ± 4.17 dB) (P = .772).
Intracameral cefuroxime did not significantly influence the thickening of macula or the subfoveal choroidal thickness in diabetic patients after uneventful cataract surgery. The functional improvement in macular sensitivity was also not affected.
评估白内障手术中玻璃体内注射头孢呋辛后糖尿病患者的黄斑和中心凹下脉络膜厚度变化以及黄斑敏感性变化。
中国上海第九人民医院眼科。
前瞻性病例系列。
将有明显视力障碍的糖尿病白内障患者分为治疗组（接受 1mg/0.1ml 头孢呋辛玻璃体内注射）和对照组（接受等量 0.9%生理盐水）。采用光学相干断层扫描测量黄斑厚度和中心凹下脉络膜厚度。采用 MP-1 微视野计评估黄斑敏感性。
本研究共纳入 38 例 46 只眼。治疗组（P<0.01）和对照组（P<0.05）术后黄斑厚度均显著增加。治疗眼平均变化量为 8.27±3.22μm，对照组为 11.38±7.75μm。术前中心凹下脉络膜厚度平均值分别为 262.86±37.02μm和 279.70±54.68μm（P=0.497）。两组间黄斑厚度变化（P=0.338）或中心凹下脉络膜厚度变化（P=0.491）无统计学差异。黄斑敏感性方面，治疗组和对照组之间的变化也无显著差异（6.05±2.37dB 与 5.52±4.17dB）（P=0.772）。
在无并发症的白内障手术后，玻璃体内注射头孢呋辛不会显著影响糖尿病患者黄斑或中心凹下脉络膜厚度的增厚，黄斑敏感性的功能改善也不受影响。
